RTP Mobile Logo
Oncology Today with Dr Neil Love: Management of Cholangiocarcinoma and Other Biliary Tract Cancers (Video Lecture)
Released July 2022

Featuring a slide presentation and related discussion from Professor Juan Valle. Published July 21, 2022. (Video Lecture)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of cholangiocarcinoma.

    LEARNING OBJECTIVES

    • Apply available clinical research findings in the formation of evidence-based therapeutic approaches for the treatment of unresectable and metastatic cholangiocarcinoma.
    • Recognize the molecular heterogeneity of cholangiocarcinomas and appreciate the biologic rationale for efforts to exploit documented abnormalities in patients with this disease.
    • Review data supporting the recent FDA approval of pemigatinib for patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement and consider how this agent can be appropriately and safely integrated into clinical management algorithms.
    • Develop an understanding of available clinical trial findings with ivosidenib for patients with advanced cholangiocarcinoma and an IDH1 mutation to determine the applicability of this therapeutic strategy in current or future clinical practice.
    • Recall available and emerging data with other investigational agents and strategies currently in clinical testing for cholangiocarcinoma, and where applicable, refer eligible patients for trial participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Interview: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Interview: Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Lecture: Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.25 (audio), 1 (video) and 0.75 (lecture) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% and fill out the Educational Assessment and Credit Form. Program location URLs are noted below:

    Audio Interview: ResearchToPractice.com/OncologyTodayCholangiocarcinoma22 and Educational Assessment and Credit Form ResearchToPractice.com/OncologyTodayCholangiocarcinoma22/CME.

    Video Interview: ResearchToPractice.com/OncologyTodayCholangiocarcinoma22/Video and Educational Assessment and Credit Form ResearchToPractice.com/OncologyTodayCholangiocarcinoma22/Video/CME.

    Video Lecture: ResearchToPractice.com/OncologyTodayCholangiocarcinoma22/Presentation and Educational Assessment and Credit Form ResearchToPractice.com/OncologyTodayCholangiocarcinoma22/Presentation/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Professor Juan W Valle, MD
    Professor of Medical Oncology
    University of Manchester
    Honorary Consultant
    The Christie NHS Foundation Trust
    Manchester, United Kingdom

    Consulting Agreements: Advanced Accelerator Applications, AstraZeneca Pharmaceuticals LP, Autem Medical, Baxter, Cantargia AB, Delcath Systems Inc, Hutchison MediPharma, Incyte Corporation, Medivir AB, Merck Sharp & Dohme LLC, NuCana, QED Therapeutics, Redx Pharma Plc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme LLC, NuCana, Redx Pharma Plc, Servier Pharmaceuticals LLC, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: Redx Pharma Plc, Taiho Oncology Inc; Speakers Bureau: Delcath Systems Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Servier Pharmaceuticals LLC.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Taiho Oncology Inc.

    Release date: July 2022
    Expiration date: July 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):